| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
It was revealed that abnormal Ca2+ increase via stretch activated ion channel (TRPV2) plays an important pathophysiological role in muscular dystrophy or cardiomyopathy. After checking safety and therapeutic potential of TRPV2 inhibition using normal and muscular dystrophic/cardiomyopathic model animals,
it was clealy revealed that TRPV2 inhibition has no toxicity in normal animals and it has good advantage on the muscular dystrophy/cardiomyopathy. On the other hand, muscle damage by cancer cachexia may be induced through TRPV2-independent mechanisms distinct from those in muscular dystrophy or cardiomyopathy.
|
